Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real‐world analysis-Reference-Cited by-同舟云学术

Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real‐world analysis

Published:2022-12 Issue:1 Volume:46 Page:50-58
ISSN:0147-8389
Container-title:Pacing and Clinical Electrophysiology
language:en
Short-container-title:Pacing Clinical Electrophis

Author:

Chugh Yashasvi¹²,Gupta Kashvi³^ORCID,Krishna Hanumanthu Balram²,Ayala Renato Quispe²,Zepeda Ignacio²,Grushko Michael²⁴,Faillace Robert T²

Affiliation:

1. Baylor Heart and Vascular Hospital Dallas Texas USA

2. Jacobi Medical Center Albert Einstein College of Medicine Bronx New York USA

3. University of Missouri at Kansas City Kansas City Missouri USA

4. Montefiore Medical Center Albert Einstein College of Medicine Bronx New York USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pace.14623

Reference35 articles.

1. The C of CHADS: Historical perspective and clinical applications for anticoagulation in patients with non valvular atrial fibrillation and congestive heart failure

2. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

3. Effect of warfarin on survival in patients with concomitant left ventricular systolic dysfunction and pulmonary hypertension: a population cohort study

4. Apixaban versus Warfarin in Patients with Atrial Fibrillation

5. Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data;European Journal of Clinical Pharmacology;2023-10-10

2. Identification of atrial fibrillation phenotypes at low risk of stroke in patients with CHA2DS2‐VASc ≥2: Insight from the China‐AF study;Pacing and Clinical Electrophysiology;2023-09-22

3. Metabolic Syndrome and Atrial Fibrillation: Different Entities or Combined Disorders;Journal of Personalized Medicine;2023-08-28

4. The Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients With Atrial Fibrillation: A Network Meta-Analysis;Cureus;2023-07-10